Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study

We studied the clinical and immunological effects of Rituximab (anti-CD20) therapy in patients with lupus nephritis. In an open clinical trial, 22 patients with active systemic lupus erythematosis and renal involvement (mainly class III and IV according to the WHO classification) that was refractory...

Descripción completa

Detalles Bibliográficos
Autores principales: Vigna-Perez, Mónica, Hernández-Castro, Berenice, Paredes-Saharopulos, Octavio, Portales-Pérez, Diana, Baranda, Lourdes, Abud-Mendoza, Carlos, González-Amaro, Roberto
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1526618/
https://www.ncbi.nlm.nih.gov/pubmed/16677395
http://dx.doi.org/10.1186/ar1954

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1526618/
https://www.ncbi.nlm.nih.gov/pubmed/16677395
http://dx.doi.org/10.1186/ar1954

Ejemplares similares